Back to News
Market Impact: 0.25
Cytosorbents Consensus Price Target Increased by 1,900% to $48.45
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for Cytosorbents was revised to $48.45 per share from $2.42 on August 25, 2026, a 1,900% increase. The figure reflects analyst targets compiled by Fintel and signals a sharply more optimistic valuation outlook, though the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
CTSO0.60
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- DST Global Advisors sells $6.86m in Chime Financial stock
- Why Radiant Logistics Stock Topped the Market on Tuesday
- DST Global Advisors sells $6.86 million in Chime Financial stock
- Micron’s 12.4x forward P/E and the case for an AI memory re-rating
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data
- Best AI Stock Research Tools for Professional Investors